References
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74.
Zhang T, Wu Q, Zhang Z. The Probable Pangolin origin of SARS Cov 2 associated with Covi19 outbreak. Curr Biol. 2020;30:1346–51.
Prasad P, Potdar V, Cherian S, et al. First image of coronavirus causing Covid-19 via TEM. Indian J Med Res. 2020. https://doi.org/10.4103/ijmr.IJMR_577_20.
Zumla A, Chan JF, Azhar EI, et al. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47.
Gorbalenya AE, Baker SC, Baric RS, et al. The coronaviridae study group of the international committee on taxonomy of viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44.
Tang X, Wu C, Li X, Song Y, Yao X, et al. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev. 2020. https://doi.org/10.1093/nsr/nwaa036.
Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA. 2020. https://doi.org/10.1073/pnas.2004999117.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.052.
Ma Y, Huang Y , Wang T, et al. ACE2 shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry. 2020. chinaXiv:202002.00082v1
Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8. https://doi.org/10.1038/s41368-020-0074-x.
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045.
Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25727.
Wang W, Xu Y, Gao R, et al. Detection of Sars-Cov-2 in different types of clinical specimens. JAMA. 2020. https://doi.org/10.1001/jama.2020.3786.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Mark N. A seattle intensivists one pager on Covid-19. https://www.onepagericu.com. 2020.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2. https://doi.org/10.1016/S2213-2600(20)30076-X.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. NEJM. 2020. https://doi.org/10.1056/NEJMoa2002032.
Hopkins C, Kumar N. Loss of sense of smell as marker of COVID-19 infection. www.entuk.org.
Cascella M, Rajnik M, Cuomo A, et al. NCBI Bookshelf, NBK554776PMID: 32150360.
Xu X, Gao X. Immunological responses against SARS-coronavirus infection in humans. Cell Mol Immunol. 2004;1(2):119–22.
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/S2468-1253(20)30057-1.
Green CA, Quraishi MN, Shabir S, et al. Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward. Lancet Gastroenterol Hepatol. 2020. https://doi.org/10.1016/S2468-1253(20).
van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020. https://doi.org/10.1056/NEJMc2004973.
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. https://doi.org/10.1001/jama.2020.4783.
Cohen J. Vaccine designers take first shots at COVID-19. Science. 2020;368(6486):14–6.
Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020. https://doi.org/10.1016/j.cell.2020.04.004(epub ahead of print).
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ramakrishna, G., Kumar, P., Aggarwal, S. et al. SARS-Cov-2 (human) and COVID-19: Primer 2020. Hepatol Int 14, 475–477 (2020). https://doi.org/10.1007/s12072-020-10049-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-020-10049-7